Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 291-296

  Lyman, Gary H ^a   Kuderer, Nicole M ^b   Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; COST MINIMIZATION ANALYSIS; DRUG COST; FEVER; GRANULOPOIESIS; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; NEUTROPENIA; PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; STEM CELL;

EID: 0031927101     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00003     Document Type: Article

References (41)

1. Pizzo PA, Hathorn JW, Heimenz JW, Browne M, Connex J, Cotton D, et al.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with neutropenia and fever. N Engl J Med 1986, 315:552-558.
2. Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors: biology and clinical application. N Engl J Med 1989, 321:1449-1459.
3. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
4. Maher DW, Graham JL, Green M, Bishop J, Stuart-Harris R, Wolf M, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994, 121:492-501.
5. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, et al.: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87:803-808.
6. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
7. Trillet-Lenoir V, Green J, Manegold C, Von Pawel JV, Gatzemeier U, Lebeau B, et al.: Recombinant granulocyte stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
8. Webster J, Kuderer NM, Lyman GH: The use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 1996, 3:519-523.
9. Smith TJ, Desch CE, Hillner BE: Efficacy and cost-effectiveness in oncology: rational allocation of cancer care resources. J Natl Cancer Inst 1993, 85:1460-1471.
10. Jönsson B, Karlsson G: Outcome measurement in economic evaluations in growth factors. Eur J Cancer 1993, 29A(supplement):S19-S22.
11. American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996, 14:1957-1960.
12. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993, 85:488-493.
13. Lyman GH, Balducci L: A cost analysis of hematopoietic colony-stimulating factors. Oncology 1995, 9:85-91.
14. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M: The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on health care costs associated with cancer chemotherapy. Eur J Cancer 1993, 29A(Suppl 7):23-30.
15. Dranitsaris G, Sutcliffe SB: Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymphoma 1995, 17:139-145.
16. Zagonel V, Babare R, Merola MC, Talamini R, Lazzarino R, Tirelli U, et al.: Cost-benefit of granulocyte-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994, 5(Suppl 2):S127-S132.
17. Rowe JM, Anderson JW, Mazza JJ, Bennett JM, Paretta E, Hayes FA, et al.: A randomized placebo controlled phase III study of GM-CSF in adult patients with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1995, 86:457-462.
18. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al.: Granulocyte-macrophage colony-stimulating factor following initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia: a double-blind, randomized study. N Engl J Med 1995, 332:1671-1677.
19. Welte K, Reiter A, Mempel K, Pfetsch M, Schweb G, Schrappe M, et al.: A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996, 87:3143-3150.
20. Souêtre E, Qing W, Pénelaud PF: Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996, 32A:1162-1165.
21. Faucher C, le Corroller AG, Blaise D, Novakovitch G, Manonni P, Moatti JP, et al.: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994, 14:895-901.
22. Uyl-deGroot CA, OssenKopple CJ, van Riet AAPM, Rutten FFH: The costs of peripheral blood progenitor cell reinfusion mobilization by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994, 30A:457-459.
23. Rusthoven JJ, deVries EGE, Dale DC, Piccart M, Glaspy J, Hamilton A: Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. Int J Antimicrobial Agents 1997, 8:263-275.
24. Mitchell PLR, Morland B, Stevens MCG, Dick G, Easlea D, Meyer LC, et al.: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997, 15:1163-1170.
25. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Maillard JA, et al.: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997, 336:1776-1780.
26. Gisselbrecht C, Haiooun C, LePage E, Bastion Y, Tilly H, Bosly A, et al.: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Leuk Lymphoma 1997, 25:289-300.
27. Lyman GH, Kuderer NM: Incorporation of quality-of-life considerations into decision models for the use of colony-stimulating factors in chemotherapy patients at risk for febrile neutropenia. In Febrile Neutropenia, Edited by Jean A Klastersky. Berlin: Springer-Verlag; 1997:17-22.
28. Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM: Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997, 15:227-236.
29. Heil G, Dieter H, Sanz MA, Lechner K, Yin JAL, Papa G, et al.: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997, 90:4710-4718.
30. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al.: Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997, 89:780-788.
31. Ganser A, Heil G: Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia. Curr Opin Hematol 1997, 4:191-195.
32. Pui C-H, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al.: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997, 336:1781-1787.
33. Bassan R, Lerede T, Di Bona E, Rossi G, Pogliani E, Rambaldi A, et al.: Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma 1997, 26:153-161.
34. Stahel RA, Jost LM, Honegger H, Betts E, Goebel ME, Nagler A, et al.: Randomized trial showing equivalent efficacy of filgrastim 5 ug/kg/d and 10 ug/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997, 15:1730-1735.
35. Duncan N, Hewetson M, Atra A, Dick G, Pinkerton R: An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children. Pharmacoeconomics 1997, 11:169-174.
36. Hartmann O, Le Corroller AG, Biaise D, Michon J, Philip I, Norol F, et al.: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997, 126:600-607.
37. Le Corroller QA-G, Faucher C, Auperin A, et al.: Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease: a randomized economic study. Pharmacoeconomics 1997, 11:454-463.
38. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al.: Randomized trial of filgrastrim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
39. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, et al.: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphomas. J Clin Oncol 1997, 15:5-10.
40. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z, et al.: G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10 and 6 micrograms/kg/day. Bone Marrow Transplant 1997, 19:215-219.
41. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Igbal A, Russell NH, et al.: Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997, 15:451-457.